AllStripes, the US-based disease research software developer formerly called RDMD, has closed a $50m series B round featuring design software provider Dassault Systèmes and medical supplies distributor McKesson.
Venture capital firm Lux Capital led the round and was also joined by Jazz Venture Partners, Spark Capital, Maveron and private investors Arif Nathoo and Leila Zegna, while McKesson and Dassault invested through subsidiaries McKesson Ventures and Medidata Solutions respectively.
Founded in 2017, AllStripes provides a research platform where patients with rare diseases can contribute their de-identified medical records to help speed up the drug development process.
AllStripes will use the funding to help expand its global presence, improve its technology and data automation capabilities, grow its team and launch 100 rare disease programmes.
Spark Capital led the company’s $14m series A round in April 2020, with Lux Capital, Village Global, Maveron and Garuda Ventures also investing. Its $3m seed round was led by Lux Capital in 2018 and included Village Global, Garuda, Shasta Ventures and a number of angel investors.
Nancy Yu, AllStripes’ co-founder and chief executive, said: “Beginning research on a rare condition can feel like being dropped into a new world without a map and we are on a mission to change that with data.
“We are proud that so many of our current investors have recognised the progress we have made and are continuing to support our vision to transform rare disease research.
“This investment will allow us to better support the rare disease community, where each person’s experience is essential to understanding disease progression – ultimately leading to new treatments for rare disease patients around the globe.”
